Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata

Fertility and Sterility

Volumn 78, Issue 1, 2002, Pages 1-12

  Sozen, Ibrahim ^a   Arici, Aydin ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Extracellular matrix; Growth factors; Leiomyoma; Myometrium; Uterus

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; ENDOTHELIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PARATHYROID HORMONE RELATED PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROLACTIN; SOMATOMEDIN A; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA;

CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FIBROGENESIS; HORMONAL REGULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENSTRUAL CYCLE; MITOGENICITY; MYOMETRIUM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UTERUS MYOMA;

CYTOKINES; EXTRACELLULAR MATRIX; FEMALE; GROWTH SUBSTANCES; HUMANS; LEIOMYOMATOSIS; UTERINE NEOPLASMS;

EID: 0036295025     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)03154-0     Document Type: Review

References (107)

1. Mesenchymal tumors of the uterus
2. Hysterectomy in the United States
3. The frequency of uterine leiomyomas
4. Estrogen-induced guinea pig model for uterine leiomyomas: Do the ovaries protect?
5. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo
6. Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma
7. Ultrastructural study of cultured smooth muscle cells from uterine leiomyoma and myometrium under the influence of sex steroids
8. Relative overexpression of collagen type 1 and collagen type 3 messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle
9. Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation
10. Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth
11. Matrix metalloproteinases as mediators of reproductive function
12. Growth factors and cytokines in uterine leiomyomas
13. Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata
14. Growth factor-mediated cell-cell interactions in the ovary
15. Growth factor and cytokine expression in the endometrium
16. Binding sites for epidermal growth factor in human uterine tissues and leiomyomas
17. Presence of messenger ribonucleic acid for epidermal growth factor (EGF) and EGF receptor demonstrable in monolayer cell cultures of myometria and leiomyomata
18. Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium
19. Quantification of messenger ribonucleic acid for epidermal growth factor in human myometrium and leiomyomata using reverse transcriptase polymerase chain reaction
20. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma
21. The binding of epidermal growth factor to myometrium and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist
22. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro
23. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF
24. Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium
25. Prolactin production from proliferative phase leiomyoma
26. Decidual type prolactin expression by the human myometrium
27. Decreased prolactin secretion by explant cultures of fibroids from women treated with gonadotropin-releasing hormone agonist
28. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium
29. Onapristone suppresses prolactin production in explant cultures of leiomyoma
30. Noncompetitive antiestrogenic effect of RU486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys
31. The molecular biology of RU 486: Is there a role for antiprogestins in the treatment of breast cancer?
32. Messenger ribonucleic acid expression of the insulin-like growth factors and their binding proteins in uterine fibroids and myometrium
33. Insulin-like growth factor 1 and 2 binding in human myometrium and leiomyomas
34. Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata
35. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues
36. Human uterine leiomyoma cells: Binding and growth responses to epidermal growth factor, platelet-derived growth factor and insulin
37. Relative overexpression of the parathyroid hormone-related peptide gene in human leiomyomas
38. In vivo regulation of parathyroid hormone-related peptide messenger ribonucleic acid in the rat uterus by 17B-estradiol
39. Growth regulatory properties of endothelins
40. Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma
41. Effect of gonadotropin-releasing hormone agonists on monocyte chemotactic protein-1 production and macrophage infiltration in leiomyomatous uterus
42. Smooth muscle cell and endothelial cell growth factors
43. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells
44. HCG promotes proliferation of uterine leiomyomal cells more strongly than that of myometrial smooth muscle cells in vitro
45. Interleukin-8 production and interleukin-8 receptor expression in human myometrium and leiomyoma
46. The transforming growth factor-β family
47. Transforming growth factor-B stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix
48. 125I]TGF-β1-binding sites
49. Modulation of transforming growth factor-B3 (TGF-B3) expression in myometrium and leiomyoma
50. Modulation of transforming growth factor-β1 (TGF-β1) expression in myometrium and leiomyoma
51. Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium
52. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF-beta 3
53. Mitotic activity in uterine leiomyomas during the menstrual cycle
54. A comparative ultrastructural study of leiomyosarcoma, cellular leiomyoma, and leiomyoma of the uterus
55. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis
56. Growth potential of human uterine leiomyomas: Some in vitro observations and their implications
57. Histopathological changes in leiomyomata treated with leuprolide acetate
58. The effect of progestins on the mitotic activity of uterine fibromyomas
59. Progesterone therapy in uterine fibromyoma
60. The progesterone therapy of human uterine leiomyomas
61. The effectiveness of medroxyprogesterone in the treatment of multiple metastasizing leiomyosarcomas: Report of a case
62. A case of so-called benign metastasizing leiomyoma responsive to progesterone
63. Autocrine secretion and malignant transformation of cells
64. Type beta transforming growth factor/growth inhibitor stimulates entry of monolayer cultures of AKR-2B cells into S phase after a prolonged prereplicative interval
65. A new type of transforming growth factor-β, TGF-β3
66. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop
67. The expression of transforming growth factor-Bs and TGF-B receptor mRNA and protein and the effect of TGF-Bs on human myometrial smooth muscle cells in vitro
68. Bidirectional effect of transforming growth factor-B1 (TGF-B1) and stimulatory effect of platelet-derived growth factor (PDGF) on mitogenesis of human myometrial and leiomyoma cells
69. Insulin-like growth factor 1 promotes leiomyoma cell growth in vitro
70. Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas
71. Prolactin is an autocrine or paracrine growth factor for human myometrial and leiomyoma cells
72. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells
73. Histological and biochemical studies on collagen in human uterine leiomyomas
74. Collagen metabolism in gynecologic patients: Changes in the concentration of the aminoterminal propeptide of type 3 procollagen in serum
75. Cell-growth promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
76. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: A mechanism for gonadotrophin releasing hormone agonist-induced tumor regression
77. Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-β1
78. Increased expression of stromelysin 3 mRNA in leiomyomas (uterine fibroids) compared with myometrium
79. Stromelysin-3 mRNA associated with myofibroblasts is overexpressed in aggressive basal cell carcinoma and in dermatofibroma but not in dermatofibrosarcoma
80. Transforming growth factor-B modulates the expression of collagenase and metalloproteinase
81. Cell surface interactions with extracellular materials
82. Transforming growth factor-B stimulates the expression of fibronectin and of both subunits of the human fibronectin receptor by cultured human lung fibroblasts
83. Alteration of cell-surface proteins by viral transformation and by proteolysis
84. Specific changes in the collagen phenotype of BALB 3T3 cells as a result of transformation by sarcoma viruses or a chemical carcinogen
85. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen
86. "Matrix algebra" heals life's wounds
87. Transforming growth factor-B1, B2 and B3 secreted by a human glioblastoma cell line: Identification of small and different forms of large latent complexes
88. Transforming growth factor-B: Activity and efficacy in animal models of wound healing
89. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1
90. Proteoglycans and neoplasia
91. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas
92. Long-term medical therapy for leiomyomata uteri: A prospective, randomized study of leuprolide acetate depot plus either estrogen-progestin or progestin 'ass-back" for two years
93. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open label Phase 2 study
94. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters
95. Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone
96. Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production
97. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor-b1
98. Control of scarring in adult wounds by neutralizing antibody to transforming growth factor b
99. Interferon-alfa is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells
100. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas
101. Inhibition of mitogenic activity of PDGF, EGF and FGF by interferon-gamma
102. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: Effects of interferon alpha-2b
103. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis
104. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27
105. Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells
106. Heparin-like molecules regulate the number of epidermal growth factor receptors on vascular smooth muscle cells
107. Novel therapeutic strategies for leiomyomas: Targeting growth factors and their receptors